These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. An outbreak of influenza B at an Indiana boarding school: estimate of vaccine efficacy. DeStefano F. Public Health Rep; 1982 Aug; 97(3):269-72. PubMed ID: 7089171 [Abstract] [Full Text] [Related]
28. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. De Filette M, Ramne A, Birkett A, Lycke N, Löwenadler B, Min Jou W, Saelens X, Fiers W. Vaccine; 2006 Jan 30; 24(5):544-51. PubMed ID: 16169634 [Abstract] [Full Text] [Related]
31. Efficacy of vaccines in chickens against highly pathogenic Hong Kong H5N1 avian influenza. Swayne DE, Beck JR, Perdue ML, Beard CW. Avian Dis; 2001 Sep 27; 45(2):355-65. PubMed ID: 11417815 [Abstract] [Full Text] [Related]
32. [Registration of the first human vaccine against the highly pathogenic avian influenza A(H5N1) virus: considerations]. de Jong JC, Osterhaus AD. Ned Tijdschr Geneeskd; 2008 Sep 27; 152(39):2113-5. PubMed ID: 18856026 [Abstract] [Full Text] [Related]
33. Influenza control in the 21st century: Optimizing protection of older adults. Monto AS, Ansaldi F, Aspinall R, McElhaney JE, Montaño LF, Nichol KL, Puig-Barberà J, Schmitt J, Stephenson I. Vaccine; 2009 Aug 13; 27(37):5043-53. PubMed ID: 19559118 [Abstract] [Full Text] [Related]
35. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine. Tamura SI, Kurata T. Jpn J Infect Dis; 2000 Jun 13; 53(3):98-106. PubMed ID: 10957706 [Abstract] [Full Text] [Related]